Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab versus tacrolimus in adult kidney transplant recipients
2025-521521-33-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Apr 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in kidney allograft rejection comparing Frexalimab arm with Tacrolimus arm (2 arms). Primary endpoint: Composite efficacy failure rate by 1 year. Planned start Apr 2026; status: authorised.
02
Drugs
frexalimabtacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2025-521521-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521521-33-00.